1-3 of 3
Yuhong Ning
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Absence Of Mutation In Cereblon (CRBN) and DNA Damage Binding Protein 1 (DDB1) Genes In Myeloma Cells and Patients and Its Clinical Significance

Anjan Thakurta, PhD, Anita K Gandhi, PhD, Michelle Waldman, MS, Chad C. Bjorklund, Ph.D., Suzanne Lentzsch, MD, PhD, Stephen A Schey, MD, Yolanda Calle, PhD, Rajani Chelliah, BSc, MSc, Robert Z. Orlowski, M.D., Ph.D, Anup Madan, PhD, Yuhong Ning, Derek Mendy, B.S., Antonia Lopez-Girona, PhD, Peter H Schafer, PhD, Herve Avet-Loiseau, MD, Rajesh Chopra, MD
Journal: Blood
Blood (2013) 122 (21): 3139.
https://doi.org/10.1182/blood.V122.21.3139.3139
Published: 2013
Journal Articles

A Comparative Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Azacitidine Following Subcutaneous (SC) and Oral Administration in Subjects with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML), Results From a Phase 1 Study.

Kyle J MacBeth, Eric Laille, Yuhong Ning, Christopher R. Cogle, MD, Barry Skikne, Steven D. Gore, MD, Guillermo Garcia-Manero, MD, M. Renee Ward, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 1772.
https://doi.org/10.1182/blood.V114.22.1772.1772
Published: 2009
Journal Articles

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Patients with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML).

Guillermo Garcia-Manero, MD, Steven D. Gore, MD, Barry Skikne, Christopher R. Cogle, MD, Yuhong Ning, Kyle J MacBeth, Eric Laille, M. Renee Ward, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 117.
https://doi.org/10.1182/blood.V114.22.117.117
Published: 2009